@article {924511,
	title = {Schedule-dependent interaction between anticancer treatments},
	journal = {Science},
	volume = {351},
	number = {6278},
	year = {2016},
	month = {2016 Mar 11},
	pages = {1204-8},
	abstract = {The oncogene MDMX is overexpressed in many cancers, leading to suppression of the tumor suppressor p53. Inhibitors of the oncogene product MDMX therefore might help reactivate p53 and enhance the efficacy of DNA-damaging drugs. However, we currently lack a quantitative understanding of how MDMX inhibition affects the p53 signaling pathway and cell sensitivity to DNA damage. Live cell imaging showed that MDMX depletion triggered two distinct phases of p53 accumulation in single cells: an initial postmitotic pulse, followed by low-amplitude oscillations. The response to DNA damage was sharply different in these two phases; in the first phase, MDMX depletion was synergistic with DNA damage in causing cell death, whereas in the second phase, depletion of MDMX inhibited cell death. Thus a quantitative understanding of signal dynamics and cellular states is important for designing an optimal schedule of dual-drug administration.},
	keywords = {Antineoplastic Agents, Apoptosis, DNA Damage, Gene Knockdown Techniques, Humans, MCF-7 Cells, Molecular Imaging, Neoplasms, Proto-Oncogene Proteins c-mdm2, RNA, Small Interfering, Signal Transduction, Time Factors, Tumor Suppressor Protein p53},
	issn = {1095-9203},
	doi = {10.1126/science.aac5610},
	author = {Chen, Sheng-Hong and Forrester, William and Lahav, Galit}
}
